Jacobs Levy Equity Management’s ImmunityBio IBRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-181,281	Closed	-$210K	–	987
2018 Q4	$210K	Buy	181,281 +135,234	+294%	+$309K	﹤0.01%	868
2018 Q3	$170K	Sell	46,047 -48,123	-51%	-$152K	﹤0.01%	942
2018 Q2	$288K	Buy	+94,170	New	+$349K	﹤0.01%	892

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management's IBRX Position: Q1 2019 in Review

Jacobs Levy Equity Management sold out of ImmunityBio (IBRX) in Q1 2019, closing a stake of 181,281 shares — an estimated $210K sold.

Jacobs Levy Equity Management first reported a position in IBRX in Q2 2018 and held it in 3 quarters. The position peaked at $288K in Q2 2018. 58 funds tracked by Wall St. Rank hold IBRX as of Q1 2019.

Jacobs Levy Equity Management reported no remaining ImmunityBio position as of Q1 2019 after selling out during the quarter.
Jacobs Levy Equity Management sold 181,281 ImmunityBio shares in Q1 2019, an estimated $210K.
Jacobs Levy Equity Management first reported a position in ImmunityBio in Q2 2018 and held it in 3 quarters.
Jacobs Levy Equity Management's ImmunityBio position peaked at $288K in Q2 2018.
58 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.